EUVIMEDEUVIMED entdecken
Crossref

A study of acromegaly-associated headache with somatostatin analgesia

Sonia Kaniuka-Jakubowska iD, Miles J Levy, Aparna Pal, Dayakshi Abeyaratne, William M Drake, Nikolaos Kyriakakis iD, Robert D Murray iD, Steve M Orme, Shailesh Gohil, Antonia Brooke, Graham P Leese, Márta Korbonits iD und 1 weitere

Endocrine-Related Cancer · 2023

DOI: 10.1530/erc-22-0138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Sonia Kaniuka-Jakubowska und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland. Hauptthemen laut MEDLINE: Acromegaly, Analgesia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study is to characterise somatostatin analogue-responsive headache in acromegaly, hitherto not systematically documented in a significant cohort. Using the UK pituitary network, we have clinically characterised a cohort of 18 patients suffering from acromegaly-related headache with a clear response to somatostatin analogues. The majority of patients had chronic migraine (78%) as defined by the International Headache Society diagnostic criteria. Headache was present at the time of acromegaly presentation and clearly associated temporally with disease activity in all cases. Short-acting somatostatin analogues uniquely resolved pain within minutes and the mean duration of analgesia was 1–6 h. Patients on long-acting analogues required less short-acting injections (mean: 3.7 vs 10.4 injections per day, P = 0.005). 94% used somatostatin analogues to control ongoing headache pain. All patients presented with macroadenoma, most had incomplete resection (94%) and headache was ipsilateral to remnant tissue (94%). Although biochemical control was achieved in 78% of patients, headache remained in 71% of them. Patients selected for this study had ongoing headache post-treatment (mean duration: 16 years after diagnosis); only four patients reached headache remission 26 years (mean range: 14–33) after the diagnosis. Headache in acromegaly patients can be persistent, severe, unrelieved by surgery, long-lasting and uncoupled from biochemical control. We show here that long-acting analogues allow a decrease in the number of short-acting analogue injections for headache relief. Further studies are needed to understand the mechanisms, markers and tumour tissue characteristics of acromegaly-related headache. Until then, this publication serves to provide the clinical characteristics as a reference point for further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyAnalgesiaHumansOctreotideSomatostatinHeadache

Stichwörter der Autor:innen

acromegaly-related headacheheadache in acromegalypituitary tumour-associated headachesomatostatin responsive headache

Substanzen

OctreotideSomatostatin

Autor:innen und Institutionen

  • Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland.
  • Department of Endocrinology at the Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Department of Endocrinology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Diabetes and Endocrinology Unit, National Hospital of Sri Lanka, Colombo, Sri Lanka.
  • Department of Endocrinology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
  • Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

ORCID-Profile: Sonia Kaniuka-Jakubowska, Nikolaos Kyriakakis, Robert D Murray, Márta Korbonits

Zitieren

APA

Kaniuka-Jakubowska, S., Levy, M. J., Pal, A., Abeyaratne, D., Drake, W. M., Kyriakakis, N., Murray, R. D., Orme, S. M., Gohil, S., Brooke, A., Leese, G. P., Korbonits, M., & Wass, J. A. (2023). A study of acromegaly-associated headache with somatostatin analgesia. Endocrine-Related Cancer. https://doi.org/10.1530/erc-22-0138

Vancouver

Kaniuka-Jakubowska S, Levy MJ, Pal A, Abeyaratne D, Drake WM, Kyriakakis N, et al. A study of acromegaly-associated headache with somatostatin analgesia. Endocrine-Related Cancer. 2023. doi:10.1530/erc-22-0138

BibTeX
@article{KaniukaJakubowska2023,
  author = {Kaniuka-Jakubowska, Sonia and Levy, Miles J and Pal, Aparna and Abeyaratne, Dayakshi and Drake, William M and Kyriakakis, Nikolaos and Murray, Robert D and Orme, Steve M and Gohil, Shailesh and Brooke, Antonia and Leese, Graham P and Korbonits, Márta and Wass, John Ah},
  title = {A study of acromegaly-associated headache with somatostatin analgesia},
  journal = {Endocrine-Related Cancer},
  year = {2023},
  doi = {10.1530/erc-22-0138}
}
Kostenlos starten →